Target Repurposing for Neglected Diseases
- 22 August 2011
- journal article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 3 (10) , 1307-1315
Abstract
Infectious diseases are an enormous burden to global health and ,since drug discovery is costly, those infectious diseases that affect the developing world are often not pursued by commercial drug-discovery efforts. Therefore, pragmatic means by which new therapeutics can be discovered are needed. One such approach is target repurposing, where pathogen targets are matched with homologous human targets that have been pursued for drug discovery for other indications. In many cases, the medicinal chemistry, structural biology and biochemistry knowledge around these human targets can be directly repurposed to launch and accelerate new drug-discovery efforts against the pathogen targets. This article describes the overarching strategy of target repurposing as a tool for initiating and prosecuting neglected disease drug-discovery programs, highlighting this approach with three case studies.Keywords
Funding Information
- National Institutes of Health (R01 AI082577)
This publication has 40 references indexed in Scilit:
- Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discoveryBMC Ecology and Evolution, 2011
- Chemical Validation of Phosphodiesterase C as a Chemotherapeutic Target in Trypanosoma cruzi , the Etiological Agent of Chagas' DiseaseAntimicrobial Agents and Chemotherapy, 2010
- N-myristoyltransferase inhibitors as new leads to treat sleeping sicknessNature, 2010
- PlasmoDB: a functional genomic database for malaria parasitesNucleic Acids Research, 2008
- Genomic-scale prioritization of drug targets: the TDR Targets databaseNature Reviews Drug Discovery, 2008
- New uses for old drugsNature, 2007
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Drug development for neglected diseases: a deficient market and a public-health policy failureThe Lancet, 2002
- Design, Activity, and 2.8 Å Crystal Structure of a C 2 Symmetric Inhibitor Complexed to HIV-1 ProteaseScience, 1990
- Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinasesFEBS Letters, 1989